EVENTS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
20th Annual Needham Virtual Healthcare Conference – Presentation
Webcast, Click Here Download Presentation, Click Here
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 8, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Presents at the 11th Annual World ADC Europe 2021 – PowerPoint Presentation
Download the presentation, CLICK HERE
Bill Newell, CEO Interviewed by Biotech 2050
Episode 47. Next Generation Cell Free Cancer and Autoimmune Therapeutics, Bill Newell, CEO, Sutro Biopharma
Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
39th Annual JP Morgan Healthcare Conference – Presentation
Webcast, CLICK HERE Download Presentation, CLICK HERE
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Presents at the American Society of Hematology (ASH) 2020 – Poster Presentation
Download the Presentation, Click Here
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular...
Bill Newell, CEO Interviewed by Moira Gunn on TechNation Radio Podcast – Episode 20-40 The Pivot From Hep B to COVID-19
TechNation’s Moria Gunn speaks with CEO Bill Newell about Sutro’s novel approach to treating cancer. Listen on Apple Podcasts